ARCHIVES

Interim Funding: Noncompeting Renewals Reduced By 4 Percent, Competing Current Plus 7 Percent

This article is from The Cancer Letter archive.

Vol. 08 No. 02 | January 8, 1982

Download PDF Visit The Full Archive

Related Articles

Phase III Trial of Alimta, Avastin Combination Fails Endpoint to Improve Overall Survival

September 28, 2012

Amgen Claimed QOL Benefit Despite FDA Label Change.

May 18, 2007

In Brief: David Johnson New ACCC President, William Dugan Named President Elect; Straus Resigns From NYMC

March 12, 1982

NTP Release Third Report On Carcinogens

January 13, 1984

Monica Bertagnolli To Succeed Schilsky As CALGB Chairman.

November 21, 2008

In Brief: Groups agree On Mammography Screening: Money Bill Markups Due After July 4 Recess

June 23, 1989